Vancouver, British Columbia – BioCure Technology Inc. (CSE: CURE, OTCQB; BICTF) (“BioCure” or the “Company”) is pleased to announce that its wholly owned subsidiary BiocurePharm Corporation (“Biocure Korea”), started conducting a pre-clinical trial of its CAR T Cell and expects the trial to be completed by the end of Q3, 2018.
Vancouver, BC - June 18, 2018 -BioCure Technology Inc. (CSE:CURE, OTCQB:BICTF) (“BioCure” or the “Company”) begins trading on OTCQB under the symbol “BICTF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
Biocure Technology Inc.'s Biocurepharm Corp. has been approved for a land purchase loan by the Industrial Bank of Korea.
As announced on Dec. 12, 2017, BP Korea entered into a land purchase agreement with Korea Land & Housing Corp. (KLHC), a state-run land and housing development company in Korea, for the acquisition of a 6,060-square-metre industrial usage parcel. The acquisition cost for the land is 2,813,950,000 Korean won (approximately $3,390,810 utilizing an exchange rate of 0.1205 cent per Korean won, June 12, 2018, Bank of Canada).
Vancouver, BC, Canada - May 31, 2018 - BioCure Technology Inc. (CSE:CURE) (“BioCure” or the “Company”) has issued an aggregate of 1.89 million share purchase warrants with an exercise price of $0.63 per share. The warrants are issuable pursuant to a services agreement dated March 22, 2017, as amended and originally entered into by the company’s wholly owned subsidiary, Biocurepharm Corp., with Columbia Capital Inc.
Vancouver, British Columbia – BioCure Technology Inc. (CSE: CURE) (“BioCure” or the “Company”) announces a non-brokered private placement (the “Private Placement”) of 1,000,000 Common Shares “Shares” at a price of $0.75 cents per Share for gross proceeds of up to $750,000.
Vancouver, British Columbia – April 11th, 2018 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure”) announces that the Company has granted to its Directors, Employees, Officers, and Consultants an aggregate of 4,150,000 options for a two-year term at an exercise price of $0.69 per share with all options vesting immediately.
Vancouver - Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the 'Company' or 'Biocure') is pleased to announce that effective April 1st, 2018, Mr. Marco Nonni has joined the board of directors of Biocure Technology Inc. Ms. Anna Dalaire is resigning from the Board effective immediately.
Vancouver, British Columbia – March 1st, 2018 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure”) is pleased to announce that effective of today’s date, Mr. Konstatin Lichtenwald will be assuming the role of CFO and has also been appointed as a director of Biocure Technology Inc.
Vancouver, British Columbia – February 20th, 2018 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure”) announces that on February 19, 2018, has entered into a contract with Osong Hi-Tech Medical Industry Promotion Foundation (“Contractor”) for non-clinical biodistribution tests of anti-CD19 CAR-T cell therapy.
Vancouver, British Columbia – February 15, 2018 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure”) announces the proposed issuance of an aggregate of 1,895,340 share purchase warrants with an exercise price to be fixed as the closing price of the Company’s shares on the CSE as at February 22, 2018 (the “Set Price”).
Biocure Technology Inc.
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
info@biocuretech.com
+1(604) 609-7146
© Biocure Technology Inc., all rights reserved
